These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29210646)

  • 1. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
    Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
    Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of PCSK9 inhibition and its effects beyond LDL receptors.
    Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A
    J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Pharmacological Approaches to Target PCSK9.
    Catapano AL; Pirillo A; Norata GD
    Curr Atheroscler Rep; 2020 Jun; 22(7):24. PubMed ID: 32495301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PCSK9 inhibitors : New treatment option in clinical practice].
    Müller-Wieland D; Marx N
    Herz; 2016 Jun; 41(4):290-5. PubMed ID: 27215418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
    Chen B; Shi X; Cui Y; Hou A; Zhao P
    Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
    Bittner VA; Giugliano RP; Brinton EA; Guyton JR
    J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.